Submitted by Anonymous (not verified) on 1 April 2026 - 16:20
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 14, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 14, Status: Authorised